Clinical trials have demonstrated that PHD inhibitors induce erythropoiesis in nephric patients suffering from any CKD stage and end-stage renal disease, but anephric patients barely respond to PHD inhibitors with regard to EPO induction (Bernhardt et al., 2010). This evidence concerns the gene PDC and chronic kidney disease.